✦ LIBER ✦

Systemic treatment of patients with gastrointestinal stromal tumor: Current status and future opportunities

✍ Scribed by George D. Demetri; Heikki Joensuu

Book ID: 118626078
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 296 KB
Volume: 6
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(08)70003-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Targeted therapy for gastrointestinal st

Targeted therapy for gastrointestinal stromal tumors: current status and future perspectives

✍ Georgios S. Papaetis; Kostas N. Syrigos 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 402 KB

Treatment Patterns And Costs Of Patients

Treatment Patterns And Costs Of Patients With Gastrointestinal Stromal Tumor (Gist) Receiving First-Line Imatinib

✍ Seal, B.; Green, M.; Stafkey-Mailey, D.; Eaddy, M. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 80 KB

Standardized concept for the treatment o

Standardized concept for the treatment of gastrointestinal dysmotility in critically ill patients—Current status and future options

✍ Michael K. Herbert; Peter Holzer 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 345 KB

Phase I study of panobinostat and imatin

Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors

✍ Bauer, S; Hilger, R A; Mühlenberg, T; Grabellus, F; Nagarajah, J; Hoiczyk, M; Re 📂 Article 📅 2014 🏛 Nature Publishing Group 🌐 English ⚖ 506 KB

Tivozanib: current status and future dir

Tivozanib: current status and future directions in the treatment of solid tumors

✍ Pal, Sumanta K; Bergerot, Paulo G; Figlin, Robert A 📂 Article 📅 2012 🏛 Informa plc 🌐 English ⚖ 430 KB

Resection of residual disease in patient

Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib

✍ Sebastian Bauer; Jörg Thomas Hartmann; Maike de Wit; Hauke Lang; Florian Grabell 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 723 KB

## Abstract Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of the gastrointestinal tract. Long‐term survival of patients with metastatic disease has only been observed in patients with completely resected disease. Recently, the tyrosine kinase inhibitor imatinib has b